CVS Health Corporation $CVS Shares Sold by Canal Insurance CO

Canal Insurance CO lowered its holdings in CVS Health Corporation (NYSE:CVS) by 8.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 210,000 shares of the pharmacy operator’s stock after selling 20,000 shares during the quarter. CVS Health comprises 3.4% of Canal Insurance CO’s investment portfolio, making the stock its 10th biggest holding. Canal Insurance CO’s holdings in CVS Health were worth $15,832,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Norges Bank purchased a new stake in shares of CVS Health during the second quarter worth about $1,358,698,000. Invesco Ltd. raised its stake in CVS Health by 15.3% during the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after purchasing an additional 3,118,626 shares during the period. Robeco Institutional Asset Management B.V. boosted its holdings in shares of CVS Health by 815.2% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock valued at $183,701,000 after purchasing an additional 2,372,121 shares during the last quarter. Kingstone Capital Partners Texas LLC purchased a new stake in shares of CVS Health during the 2nd quarter valued at $155,185,000. Finally, Jennison Associates LLC increased its holdings in shares of CVS Health by 111.7% during the 2nd quarter. Jennison Associates LLC now owns 4,014,139 shares of the pharmacy operator’s stock worth $276,895,000 after buying an additional 2,117,798 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Bernstein raised its price target to $91 and reaffirmed a Market Perform rating, signaling incremental analyst support for a higher valuation and helping sentiment on the name. Bernstein raises PT on CVS Health (CVS) to $91, reiterates ‘market perform’ rating
• Positive Sentiment: Gilead said its new HIV prevention shot has been added to CVS’s drug coverage lists for commercial plans — a win for pharmacy and PBM revenue mix and utilization that could lift prescription volume and margins. Gilead’s new HIV prevention shot added to CVS’s drug coverage lists, CEO says
• Positive Sentiment: High-profile media commentary (Jim Cramer) highlighting CEO Karen Lynch/management execution (“Joyner’s money”) is boosting investor confidence in leadership and strategy. Jim Cramer on CVS CEO: “Joyner’s Money”
• Neutral Sentiment: Research outlets (Zacks) are publishing favorable screens on CVS as a top-ranked value and momentum stock and highlighting strong earnings surprise history — these pieces raise investor attention but are informational unless followed by concrete catalyst. CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
• Neutral Sentiment: Zacks coverage also notes heavy investor searches and discusses the company’s likelihood of beating upcoming estimates — increased attention can boost liquidity and short-term momentum but isn’t a direct fundamental change. Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
• Negative Sentiment: An Illinois risk pool has sued Eli Lilly, CVS and UnitedHealth over insulin pricing — this litigation adds regulatory and legal risk, potential damages and reputational downside that could pressure the stock if claims escalate or lead to material fines. Illinois risk pool sues Eli Lilly, CVS, UnitedHealth over insulin pricing

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Robert W. Baird boosted their price target on CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Wolfe Research boosted their target price on CVS Health from $85.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Weiss Ratings restated a “hold (c-)” rating on shares of CVS Health in a report on Monday, December 29th. Wells Fargo & Company decreased their price objective on shares of CVS Health from $103.00 to $102.00 and set an “overweight” rating for the company in a research note on Thursday, November 13th. Finally, UBS Group reissued an “outperform” rating on shares of CVS Health in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and a consensus price target of $94.86.

CVS Health Stock Performance

NYSE:CVS opened at $80.63 on Wednesday. CVS Health Corporation has a 1-year low of $50.14 and a 1-year high of $85.15. The stock has a market cap of $102.36 billion, a P/E ratio of 212.20, a PEG ratio of 0.74 and a beta of 0.48. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. The firm has a 50-day moving average of $78.78 and a two-hundred day moving average of $74.10.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.24. The company had revenue of $102.87 billion for the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.CVS Health’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd will be paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Thursday, January 22nd. CVS Health’s dividend payout ratio is 700.00%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.